Episode 60
Biotech Hangout
00:00
The Risk of Spending Big Box in Later Stages of Development
Paul Abdi was the head of research at J&J for a very long time. He brought 25 novel medicines across the finish line there. And he already made a couple of small deals last year, and I have to say the market really yawned at these. So he bought a cell therapy company called CellPoint that's partnered with Lanza. The idea is to do CAR-T at the point of care.
Transcript
Play full episode
